Alev KURAL, Elif Eda ÖZER, Gülşen Pınar SOYDEMİR

Meme Kanseri Radyoterapisinde Enflamasyon Belirteçleri Değişimi

GİRİŞ ve AMAÇ: Kronik enflamasyon, kanser gelişimi ve progresyonunda kilit rol oynar. Radyoterapi (RT) sırasında da, enflamasyonu ve oksidatif stresi indükleyen akut faz proteinleri üretilir. Bu proteinlerden ikisi C reaktif protein (CRP) ve albümindir (Alb). Bu çalışmada RT sırasında akut faz proteinlerinin seviyelerinin radyasyon ve diğer faktörler ile ilişkisinin araştırılması amaçlanmıştır. YÖNTEM ve GEREÇLER: Çalışmamıza meme kanseri tanısı alan 50 kadın hasta dâhil edildi. Tüm hastalara adjuvan RT uygulandı. RT öncesi ve RT nin son günü hastaların rutin CRP ve Alb seviyeleri bakıldı. RT öncesi ve sonrası değerler ile hastaların evresi, RT alanları ve akut RT yan etki dereceleri arasındaki ilişki değerlendirildi. BULGULAR: RT öncesi ve sonrası CRP ve Alb değerleri istatistiksel olarak incelendiğinde CRP’ nin anlamlı seviyede yükseldiği (0,033) Alb’in ise anlamlı derecede düştüğü (p: 0,020) bulunmuştur. Hastaların evresi ile Alb ve CRP değişimi arasında anlamlı ilişki saptanmadı. Ancak RT alanına supraklavikuler ve aksiller RT’nin eklenmesiyle CRP değişimi arasında anlamlı ilişki saptanmıştır. Meme ya da göğüs duvarı RTsine supraklavikuler ve aksiller RT eklenen olgu grubunda RT sırasına CRP düzeyinin istatistiksel olarak anlamlı şekilde arttığı tespit edilmiştir. TARTIŞMA ve SONUÇ: Sonuç olarak radyasyon tedavisinin CRP ve albümin seviyesinde değişikliğe neden olduğunu ve bu değişimlerin RT ile birlikte multiple faktöre bağlı olduğunu göstermiştir.

Change in Inflammation Markers in Breast Cancer Radiotherapy

INTRODUCTION: Chronic inflammation plays a key role in cancer development and progression. During radiotherapy (RT), acute- phase proteins are produced that induce inflammation and oxidative stress. Two of these proteins are C reactive protein (CRP) and albümin (Alb). In this study we aimed to investigate the relationship of acute phase proteins levels with radiation and other factors during radiotherapy. METHODS: 50 female patients diagnosed with breast cancer were included in our study. Adjuvant RT was applied to all patients. Routine CRP and Alb levels of the patients were evaluated before RT and on the last day of RT. The relationship between the stage of patients, RT areas and acute radiation side effects were evaluated. RESULTS: When CRP and Alb levels were evaluated before and after the treatment, a significant increase was found in CRP and a significant decrease was found in Alb. There was no significant relationship between the stage of the patients and the change in Alb, CRP. However, a significant relationship was found between the CRP change with the addition of supraclavicular and axillary RT. DISCUSSION AND CONCLUSION: As a result it has been shown that radiation therapy causes changes in CRP and Alb levels and these changes depend on multiple factors along with RT.

PDF

___

1. Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860-867.
2. DeNardo DG, Coussens LM. Inflammation and breast cancer: Balancing immune response—Crosstalk between adaptive and innate immune cells during breast cancer progression. Breast Cancer Res. 2007; 9: 212,
3. O’Hanlon DM, Lynch J, Cormican M, et al. The acute phase response in breast carcinoma. Anticancer Res 2002; 22: 1289-1293,
4. Blann AD, Byrne GJ, Baildam AD. Increased soluble intercellular adhesion molecule-1, breast cancer and the acute phase response. Blood Coagul Fibrinolysis 2002;13:165-168.
5. Al Murri AM, Bartlett JM, Canney PA, et al. Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 2006; 94:227-230,
6. Zimmerman MA, Selzman CH, Cothren C et al. Diagnostic implications of C-reactive protein. Arch Surg. 2003;138(2):220-224. 7. Elliott RL, Blobe GC. Role of transforming growth factor beta in human cancer. J Clin Oncol. 2005;23(9):2078-2093
8. Simons Jean Paul F. H. A. , Schols A.M.W. J., Buurman W. A. et al., Weight loss and low body cell mass in males with lung cancer: relationship with systemic inflammation, acutephase response, resting energy expenditure, and catabolic and anabolic hormones, Clinical Science, 1999; 97, 2: 215–223,
9. Pierce BL, Ballard-Barbash R, Bernstein L, et al. Elevated biomarkers of inflammation are associated with reduced survival among breast cancer patients. J Clin Oncol. 2009;27(21):3437-3444.
10. Fukuchi M, Kuwabara K, Tsuji Y, et al. C-reactive protein is anegative independent factor in patients with stage IV colorectalcancer undergoing oxaliplatin-based chemotherapy. Anticancer Res. 2013;33(11):5051-5055.
11. Jin Y, Sun Y, Shi X et al. Prognostic value of circulating C-reactive protein levels in patients with non-small cell lung cancer: a systematic review with meta-analysis. J Cancer Res Ther. 2014;10(Suppl):C160-166.
12. Stark JR, Li H, Kraft P, et al. Circulating prediagnostic interleukin-6 and C-reactive protein and prostate cancer incidence and mortality. Int J Cancer. 2009;124(11):2683-2689.
13. Thurner EM, Krenn-Pilko S, Langsenlehner U, et al. The elevated C-reactive protein level is associated with poor prognosis in prostate cancer patients treated with radiotherapy. Eur J Cancer. 2015;51(5):610-619.
14. Karakiewicz PI, Hutterer GC, Trinh QD, et al. C-reactive protein is an informative predictor of renal cell carcinoma-specific mortality: a European study of 313 patients. Cancer. 2007;110(6): 1241-1247.
15. Haas M, Heinemann V, Kullmann F, et al. Prognostic value of CA 19-9, CEA, CRP, LDH and bilirubin levels in locally advanced and metastatic pancreatic cancer: results from a multicenter,pooled analysis of patients receiving palliative chemotherapy. J Cancer Res Clin Oncol. 2013;139(4):681-689.
16. Siegel RL, Miller KD, Jemal A: Cancer Statistics,2017. CA Cancer J Clin 2017; 67:7-30,
17. Darby S, McGale P, Correa C, et al: Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: Meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 2011;378:1707-1716.
18. McGale P, Taylor C, Correa C, et al: Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: Meta-analysis of individual patient data for 8135 women in 22 randomised trials. Lancet 2014;383:2127-2135.
19. Poleszczuk J, Luddy K, Chen L, et al: Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival. Breast Cancer Res 2017;19:75.
20. Gallet P, Phulpin B, Merlin JL, et al: Long-term alterations of cytokines and growth factors expression in irradiated tissues and relation with histological severity scoring. PLoS One 2011; 6:e29399.
21. Citrin DE, Hitchcock YJ, Chung EJ, et al: Determination of cytokine protein levels in oral secretions in patients undergoing radiotherapy for head and neck malignancies. Radiat Oncol 2012; 7:64.
22. Gabay C, Kushner I. Acute phase response proteins and other systemic response to inflammation. N Engl J Med 1999;340(6):448–454.
23. Tang JT, Yamazaki H, Nishimoto N, et al. Effect of radiotherapy on serum level of interleucin 6 in patients with cervical carcinoma. Anticancer Res 1996; 16:2005–2008
24. Hu JJ, Urbanic JJ, Case LD, et al. Association Between Inflammatory Biomarker C-Reactive Protein and Radiotherapy-Induced Early Adverse Skin Reactions in a Multiracial/Ethnic Breast Cancer Population. J Clin Oncol. 2018;36(24):2473–2482.
25. Scott HR, McMillan DC, Forrest LM et al. The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable nonsmall cell lung cancer. Br J Cancer 2002; 87:264-267
26. McMillan DC, Elahi MM, Sattar N et al. Measurement of the systemic inflammatory response predicts cancer-specific and non-cancer survival in patients with cancer. Nutr Cancer 2001; 41: 64-69.
27. Schumacher K, Haensch W, Roefzaad C et al. Prognostic significance of activated CD8 (+) T cell infiltrations within esophageal carcinomas.Cancer Res 2001; 61: 3932-3936
28. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer. 1981;47(1):207-214
29. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92
30. Forrest LM, McMillan DC, McArdle CS, Angerson scores based on the systemic inflammatory response in patients with inoperable nonsmall-cell lung cancer. Br J Cancer 2003; 89:1028-1030.
31. Ikeda M, Natsugoe S, Ueno S et al. Significant host- and tumorrelated factors for predicting prognosis in patients with esophageal carcinoma. Ann Surg 2003; 238: 197-202.
32. Nozoe T, Saeki H, Sugimachi K. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg 2001; 182: 197-201.
33. Shimada H, Nabeya Y, Okazumi S et al. Elevation of preoperative serum C reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol 2003;83: 248-252.
35. Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC. Evaluation of an inflammation- based prognostic score in patients with inoperable gastrooesophageal cancer. Br J Cancer 2006; 94: 637-641.
36. Chang-Yu Wang, Ming-Jang Hsieh, Yi-Chun Chiu et al. Higher serum C-reactive protein concentration and hypoalbuminemia are poor prognostic indicators in patients with esophageal cancer undergoing radiotherapy. Radiother Oncol 2009; 92: 270-275.
37. McMillan DC, Crozier JE, Canna K. et al. Evaluation of an inflammationbased prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis 2007; 22: 881-886.
38. Hashimoto K, Ikeda Y, Korenaga D. et al. The impact of preoperative serum C reactive protein on the prognosis of patients with hepatocellular carcinoma. Cancer 2005; 103: 1856-1864.
39. Kodama J, Miyagi Y, Seki N. et al. Serum C-reactive protein as a prognostic factor in patients with epithelial ovarian cancer. Eur J Obstet Gynecol Reprod Biol 1999; 82: 107-110.
40. Nakanishi H, Araki N, Kudawara I. et al. Clinical implications of serum Creactive protein levels in malignant fibrous histiocytoma. Int J Cancer 2002; 99: 167-170.
41. Murri AM, Bartlett JM, Canney PA et al. Evaluation of an inflammation-based prognostic score (GPS) in patients with metastatic breast cancer. Br J Cancer 2006; 94: 227-230.
42. Ramsey S, Lamb GW, Aitchison M. et al. Evaluation of an inflammationbased prognostic score in patients with metastatic renal cancer. Cancer 2007; 109: 205-212.
43. Glen P, Jamieson NB, McMillan DC. et al., 0Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology 2006; 6: 450-453.
44. Kuroda K, Tasaki S, Horiguchi A. et al. Postoperative C-reactive protein-to-albumin ratio predicts poor prognosis in patients with bladder cancer undergoing radial cystectomy. Mol Clin Oncol. 2021 Mar;14(3):54.